Last reviewed · How we verify
NCT05091879
Implementation and Evaluation of Preemptive Pharmacogenomics Testing in an Aging Population
NA trial testing Multigene pharmacogenomics test in Polypharmacy in 66 participants. Participants enrolled and being followed up; not accepting new ones.
1 June 2026
Quick facts
| Lead sponsor | Geisinger Clinic |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 66 |
| Start date | 28 March 2023 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Multigene pharmacogenomics test
Conditions studied
- Polypharmacy — all drugs for Polypharmacy →
- Pharmacogenomic Testing — all drugs for Pharmacogenomic Testing →
Sponsor
Geisinger Clinic
Who can join
65 and older, any sex, with Polypharmacy or Pharmacogenomic Testing. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Number of pharmacogenomic results returned in patients' health records
Time frame: Date of blood draw to test results reported in medical record, up to 1 month
The primary objective will be assessed by comparing the total number of patients with returned results in the electronic health record (EHR) with the total number of tested patients.
Sponsor's own description
The primary goal of this study is to conduct pharmacogenomics testing (a type of DNA test) within an aging population and measure the impact of this test on medication selection, dosing, and costs of care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05091879
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Polypharmacy
Currently open trials in the same condition.
- NCT06110156 — Population Health Approach to Optimizing Medications in Older Adults · NA · active not recruiting
- NCT07022990 — Improving Medication Management in World Trade Center Responders · NA · recruiting
- NCT06451692 — Prioritising Patient Medication Review: Hospitals Reaching Out · NA · recruiting
- NCT05526963 — Reduction of Polypharmacy in Elderly People With Multiple Diseases · NA · recruiting
- NCT06273761 — Evaluation of Medication Management Service · NA · recruiting
Other Geisinger Clinic trials
Trials by the same sponsor.
- NCT07197801 — Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Diso · NA · recruiting
- NCT06936709 — Perioperative Colchicine for TKA · Phase 4 · not yet recruiting
- NCT07042477 — Integrated Telemedicine Program Evaluation · NA · recruiting
- NCT07028398 — CMSL Ambulatory Sensitive Condition Nudge Study 2 · NA · recruiting
- NCT06696066 — PEERS Pilot: Peer Recovery Support Program to Support Engagement in Medication for Opioid Use Disorder · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05091879 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Geisinger Clinic
- Last refreshed: 25 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05091879.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing